NEW YORK — Genetron Health on Thursday reported a 40 percent year-over-year rise in revenues for the second quarter on strong sales from its cancer diagnosis and monitoring operations, which include lab-developed tests (LDTs) and in vitro diagnostics (IVDs).
Beijing-based Genetron, which went public in the US in June to raise $235.0 million, posted second quarter revenues of RMB101.7 million ($14.6 million) versus RMB72.5 million in the year-ago period.